Qiagen Sees Brighter Reimbursement Outlook For Companion Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Personalized health care remains an important growth driver for the diagnostics developer, which is juggling some 15 companion diagnostics projects. The reimbursement landscape for FDA-approved tests is improving, Qiagen says.
You may also be interested in...
Diagnostics News: Qiagen Companion Dx; Ortho-Clinical Agreement; BD 510(k)s
Qiagen will co-develop and commercialize a companion diagnostic for AstraZeneca’s Iressa lung-cancer drug under an agreement between the firms. Ortho-Clinical Diagnostics will sell a test system for acute kidney injury. BD nabs 510(k)s for STD assays.
Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”